These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 34250395)

  • 21. Oncolytic Viruses in Cancer Treatment: A Review.
    Lawler SE; Speranza MC; Cho CF; Chiocca EA
    JAMA Oncol; 2017 Jun; 3(6):841-849. PubMed ID: 27441411
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oncolytic Virotherapy and Gene Therapy Strategies for Hepatobiliary Cancers.
    Yamada T; Hamano Y; Hasegawa N; Seo E; Fukuda K; Yokoyama KK; Hyodo I; Abei M
    Curr Cancer Drug Targets; 2018; 18(2):188-201. PubMed ID: 28359239
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The discovery and development of oncolytic viruses: are they the future of cancer immunotherapy?
    Zhang S; Rabkin SD
    Expert Opin Drug Discov; 2021 Apr; 16(4):391-410. PubMed ID: 33232188
    [No Abstract]   [Full Text] [Related]  

  • 24. Optimization and preclinical design of genetically engineered viruses for human oncolytic therapy.
    Hiss DC; Fielding BC
    Expert Opin Biol Ther; 2012 Nov; 12(11):1427-47. PubMed ID: 22788715
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The two-faces of NK cells in oncolytic virotherapy.
    Marotel M; Hasim MS; Hagerman A; Ardolino M
    Cytokine Growth Factor Rev; 2020 Dec; 56():59-68. PubMed ID: 32586674
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design and application of oncolytic viruses for cancer immunotherapy.
    Ylösmäki E; Cerullo V
    Curr Opin Biotechnol; 2020 Oct; 65():25-36. PubMed ID: 31874424
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Arming oncolytic viruses to leverage antitumor immunity.
    de Gruijl TD; Janssen AB; van Beusechem VW
    Expert Opin Biol Ther; 2015 Jul; 15(7):959-71. PubMed ID: 25959450
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oncolytic viruses and their application to cancer immunotherapy.
    Chiocca EA; Rabkin SD
    Cancer Immunol Res; 2014 Apr; 2(4):295-300. PubMed ID: 24764576
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The emergence of combinatorial strategies in the development of RNA oncolytic virus therapies.
    Nguyen TL; Tumilasci VF; Singhroy D; Arguello M; Hiscott J
    Cell Microbiol; 2009 Jun; 11(6):889-97. PubMed ID: 19388908
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oncolytic virotherapy: Challenges and solutions.
    Goradel NH; Baker AT; Arashkia A; Ebrahimi N; Ghorghanlu S; Negahdari B
    Curr Probl Cancer; 2021 Feb; 45(1):100639. PubMed ID: 32828575
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oncolytic viruses: overcoming translational challenges.
    Martinez-Quintanilla J; Seah I; Chua M; Shah K
    J Clin Invest; 2019 Mar; 129(4):1407-1418. PubMed ID: 30829653
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of oncolytic virotherapy: from genetic modification to combination therapy.
    Lan Q; Xia S; Wang Q; Xu W; Huang H; Jiang S; Lu L
    Front Med; 2020 Apr; 14(2):160-184. PubMed ID: 32146606
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Determinants of the efficacy of viro-immunotherapy: A review.
    de Graaf JF; Huberts M; Fouchier RAM; van den Hoogen BG
    Cytokine Growth Factor Rev; 2020 Dec; 56():124-132. PubMed ID: 32919831
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic Efficacy of Oncolytic Viruses in Fighting Cancer: Recent Advances and Perspective.
    Garmaroudi GA; Karimi F; Naeini LG; Kokabian P; Givtaj N
    Oxid Med Cell Longev; 2022; 2022():3142306. PubMed ID: 35910836
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evolution of oncolytic viruses: novel strategies for cancer treatment.
    Atherton MJ; Lichty BD
    Immunotherapy; 2013 Nov; 5(11):1191-206. PubMed ID: 24188674
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic modification of oncolytic viruses to enhance antitumor immunity.
    Davola ME; Vito A; Wei J; El-Sayes N; Workenhe S; Mossman KL
    Methods Enzymol; 2020; 635():231-250. PubMed ID: 32122548
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study.
    Marchini A; Daeffler L; Pozdeev VI; Angelova A; Rommelaere J
    Front Immunol; 2019; 10():1848. PubMed ID: 31440242
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intraarterial delivery of virotherapy for glioblastoma.
    Srinivasan VM; Lang FF; Kan P
    Neurosurg Focus; 2021 Feb; 50(2):E7. PubMed ID: 33524944
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Erythrocyte-Leveraged Oncolytic Virotherapy (ELeOVt): Oncolytic Virus Assembly on Erythrocyte Surface to Combat Pulmonary Metastasis and Alleviate Side Effects.
    Liu M; Zhang R; Huang H; Liu P; Zhao X; Wu H; He Y; Xu R; Qin X; Cheng Z; Liu H; Ergonul O; Can F; Ouyang D; Wang Z; Pang Z; Liu F
    Adv Sci (Weinh); 2024 Feb; 11(5):e2303907. PubMed ID: 37997186
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Permissiveness of human cancer cells to oncolytic bovine herpesvirus 1 is mediated in part by KRAS activity.
    Cuddington BP; Mossman KL
    J Virol; 2014 Jun; 88(12):6885-95. PubMed ID: 24696490
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.